[go: up one dir, main page]

BRPI0411364A - compostos tendo atividade inibidora de fosfatidilinositol 3-cinase e métodos de uso dos mesmos - Google Patents

compostos tendo atividade inibidora de fosfatidilinositol 3-cinase e métodos de uso dos mesmos

Info

Publication number
BRPI0411364A
BRPI0411364A BRPI0411364-0A BRPI0411364A BRPI0411364A BR PI0411364 A BRPI0411364 A BR PI0411364A BR PI0411364 A BRPI0411364 A BR PI0411364A BR PI0411364 A BRPI0411364 A BR PI0411364A
Authority
BR
Brazil
Prior art keywords
compounds
methods
phosphatidylinositol
inhibitory activity
kinase inhibitory
Prior art date
Application number
BRPI0411364-0A
Other languages
English (en)
Inventor
Beth E Drees
Leena Chakravarty
Glenn D Prestwich
Gyorgy Dorman
Mariann Kavecz
Andras Lukacs
Laszlo Urge
Ferenc Darvas
Piotr W Rzepecki
Collin G Ferguson
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of BRPI0411364A publication Critical patent/BRPI0411364A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

"COMPOSTOS TENDO ATIVIDADE INIBIDORA DE FOSFATIDILINOSITOL 3-CINASE E MéTODOS DE USO DOS MESMOS". A presente invenção refere-se a compostos inibindo as atividades de fosfatidilinositol 3-cinase (PI 3-K) e métodos de preparação e uso dos mesmos no tratamento de doenças são descritos. Os compostos que inibem a atividade da PI 3-K e métodos de uso de compostos inibidores de PI 3-K para inibir o crescimento de célula cancerosa ou para tratar distúrbios de imunidade e inflamação, onde PI 3-K desempenha um papel no funcionamento de leucócito são também providos.
BRPI0411364-0A 2003-06-13 2004-06-14 compostos tendo atividade inibidora de fosfatidilinositol 3-cinase e métodos de uso dos mesmos BRPI0411364A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47822103P 2003-06-13 2003-06-13
PCT/US2004/018752 WO2005016245A2 (en) 2003-06-13 2004-06-14 Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI0411364A true BRPI0411364A (pt) 2006-07-25

Family

ID=34193025

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411364-0A BRPI0411364A (pt) 2003-06-13 2004-06-14 compostos tendo atividade inibidora de fosfatidilinositol 3-cinase e métodos de uso dos mesmos

Country Status (13)

Country Link
US (1) US20070010548A1 (pt)
EP (1) EP1648463A2 (pt)
JP (1) JP2007500249A (pt)
KR (1) KR20060070486A (pt)
CN (1) CN1823067A (pt)
AU (1) AU2004264834A1 (pt)
BR (1) BRPI0411364A (pt)
CA (1) CA2528938A1 (pt)
IL (1) IL172426A0 (pt)
NO (1) NO20060210L (pt)
RU (1) RU2006100484A (pt)
WO (1) WO2005016245A2 (pt)
ZA (1) ZA200509961B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51351B (en) * 2005-07-20 2011-02-28 Aventis Pharma S.A. 1,4-DIHYDROPYRIDINE-CONDENSED HTEROCYCLES, PROCEDURES FOR THEIR PRODUCTION, USE AND THE COMPOSITIONS CONTAINING THEM
US20070238746A1 (en) 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
US7517995B2 (en) * 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
EP2952186A1 (en) * 2007-03-26 2015-12-09 University Of Southern California Compositions for inducing apoptosis by stimulating ER stress
ES2445199T3 (es) 2008-06-05 2014-02-28 Glaxo Group Limited Derivados de benzpirazol como inhibidores de PI3-quinasas
US8765743B2 (en) 2008-06-05 2014-07-01 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2009147187A1 (en) * 2008-06-05 2009-12-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
ES2526966T3 (es) * 2008-06-05 2015-01-19 Glaxo Group Limited Compuestos novedosos
MX2011000729A (es) * 2008-07-29 2011-03-15 Boehringer Ingelheim Int 5-alquinil-pirimidinas.
ES2542551T3 (es) 2009-03-09 2015-08-06 Glaxo Group Limited 4-Oxadiazol-2-il-indazoles como inhibidores de PI3 cinasas
RS53830B1 (en) 2009-04-30 2015-06-30 Glaxo Group Limited INDASOLS SUBSTITUTED BY OXAZOLE AS PI3-KINASE INHIBITORS
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
JP2013512879A (ja) * 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
EP2507226A1 (en) * 2009-12-03 2012-10-10 Glaxo Group Limited Novel compounds
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
US9096594B2 (en) * 2012-10-12 2015-08-04 The Broad Institute, Inc. Kinase inhibitors and methods of use thereof
SG11202000523PA (en) 2017-07-31 2020-02-27 The Trustees Of Columbia Univeristy In The City Of New York Compounds, compositions, and methods for treating t-cell acute lymphoblastic leukemia
WO2023220131A2 (en) * 2022-05-10 2023-11-16 Relay Therapeutics, Inc. PI3Kα INHIBITORS AND METHODS OF USE THEREOF
CN115353515A (zh) * 2022-09-08 2022-11-18 南京苏亦欣医药科技有限公司 一种医药中间体吡唑并喹啉酮衍生物的制备方法及催化剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3935222A (en) * 1975-04-16 1976-01-27 E. R. Squibb & Sons, Inc. 1,4,5,7-Tetrahydropyrazolo[3,4-b]pyridin-6-ones
GR79111B (pt) * 1982-12-20 1984-10-02 Lepetit Spa

Also Published As

Publication number Publication date
US20070010548A1 (en) 2007-01-11
ZA200509961B (en) 2006-10-25
AU2004264834A1 (en) 2005-02-24
IL172426A0 (en) 2006-04-10
CA2528938A1 (en) 2005-02-24
RU2006100484A (ru) 2006-06-10
KR20060070486A (ko) 2006-06-23
WO2005016245A2 (en) 2005-02-24
JP2007500249A (ja) 2007-01-11
CN1823067A (zh) 2006-08-23
WO2005016245A3 (en) 2005-06-02
EP1648463A2 (en) 2006-04-26
NO20060210L (no) 2006-03-01

Similar Documents

Publication Publication Date Title
BRPI0411364A (pt) compostos tendo atividade inibidora de fosfatidilinositol 3-cinase e métodos de uso dos mesmos
DK1438052T3 (da) Quinazolin-4-oner af inhibitorer som human phosphatidylinositol 3-kinase delta
DK1278748T3 (da) Inhibitorer af human phosphatidyl-inositol 3-kinase delta
BRPI0312464B8 (pt) compostos inibidores de tirosina quinases, composições farmacêuticas compreendendo os mesmos, processos para fabricação e usos dos mesmos
BR0008365A (pt) 2-amino-6-anilino-purinas e o seu uso comomedicamento
BRPI0415395A (pt) composto, métodos para inibir a atividade da proteìna quinase e para tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase, e, composição
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
EP2612862A3 (en) Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
BR9709443B1 (pt) n-7-heterociclil-pirrol[2,3-d]pirimidinas, bem como composições farmacêuticas compreendendo as mesmas.
YU49101A (sh) Karboksiaril supstituisani difenil karbamidi kao inhibitori raf kinaze
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
BR0315662A (pt) Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona
BRPI0513513A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito inibitório de eg5 e um efeito anticáncer em um animal de sangue quente, e para tratar carcinomas em um animal de sangue quente
BR0200921A (pt) Uso de produtos de legume para o tratamento de agressões externas
BR0213037A (pt) Derivados de pirimidina
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
EP1939203A3 (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform
WO2005002514A3 (en) Compounds having inhibitibe activity of phosphatidylinositol 3-kinase and methods of use thereof
ATE311901T1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
BR0303384A (pt) Citalopram e seus usos no tratamento de pressão sanguìnea elevada

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: ZENTARIS GMBH (DE)

Free format text: SEDE ALTERADA CONFORME PETICAO NO 020060058923-RJ DE 27.04.2006.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.